Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study

Approximately two-thirds of patients who present with small-cell lung cancer (SCLC) have extensive-stage SCLC (ES-SCLC), reflecting the highly aggressive nature of this tumor and its tendency for early, widespread metastasis [1,2]. Less than 5% of patients with ES-SCLC remain alive at 2 years after diagnosis [3]. Progress in improving outcomes for patients with ES-SCLC has been limited until recently. Standard first-line treatment has consisted of etoposide in combination with either carboplatin or cisplatin (EP) for more than three decades [4 –6].

Source: Lung Cancer - September 9, 2020 Category: Cancer & Oncology Authors: Jonathan W. Goldman, Marina Chiara Garassino, Yuanbin Chen, Mustafa Özgüroğlu, Mikhail Dvorkin, Dmytro Trukhin, Galina Statsenko, Katsuyuki Hotta, Jun Ho Ji, Maximilian J. Hochmair, Oleksandr Voitko, Libor Havel, Artem Poltoratskiy, György Losonczy, N Source Type: research